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Abstract: Background: Single-pill combinations of aliskiren/hydrochlorothiazide have recently been approved by the 
European Medicines Agency for the treatment of hypertension. 
Objective: This study aimed to assess the antihypertensive efficacy of aliskiren/hydrochlorothiazide combination in   
reducing systolic and diastolic blood pressure in hypertensive patients. 
Methods: A search in International Pharmaceutical Abstracts, MEDLINE, The Cochrane Library and ISI Web of Knowl-
edge was performed from 2000 to November 2009, to identify randomized, double-blind, clinical trials using   
aliskiren/hydrochlorothiazide for the treatment of hypertension. Studies were included if they evaluated the antihyperten-
sive efficacy of aliskiren/hydrochlorothiazide in patients with mild or moderate essential hypertension and age  18 years. 
The meta-analytical approach calculated the weighted average reductions of systolic and diastolic blood pressure for each 
daily dosage combination. 
Results: We included 5 clinical trials testing several combinations of aliskiren/hydrochlorothiazide and containing data on 
5448 patients. In all studies blood pressure was assessed at inclusion (baseline) and after 8 weeks of therapy. Blood pres-
sure reductions and control rates were significantly (p < 0.05) higher with the aliskiren/hydrochlorothiazide combinations 
than with placebo and the same doses of aliskiren or hydrochlorothiazide alone. The weighted mean reductions (mm Hg) 
from baseline of systolic and diastolic blood pressure for each aliskiren/hydrochlorothiazide combination were: -15.8/-
10.3 (150/25 mg); -15.9/-11.8 (300/12.5 mg); -16.9/-11.6 (300/25 mg). Blood pressure control rates (%) for the above 
combinations were, at least, respectively: 43.8, 50.1 and 51.9. 
Conclusions: Aliskiren/hydrochlorothiazide provided clinically significant additional blood pressure reductions and   
improved blood pressure control rates over aliskiren or hydrochlorothiazide monotherapy. 
Keywords: Aliskiren; aliskiren-hydrochlorothiazide; combination therapy; hypertension; blood pressure; antihypertensives. 
INTRODUCTION 
  Hypertension is a major risk factor in the development of 
cardiovascular disease, heart attack and stroke and one of the 
most important public health problems worldwide due to its 
high prevalence and deleterious impact on the population in 
terms of excessive morbidity and mortality. Currently, hy-
pertension is estimated to affect approximately 30% of the 
US and European population and 1 billion people worldwide 
and, as the population ages, this number is expected to in-
crease even further. Moreover, despite advances in treatment 
of the condition, hypertension control rates continue to be 
suboptimal in both the US and Europe as only about one 
third have their blood pressure (BP) reduced to the recom-
mended levels by the 7
th Joint National Committee (JNC-7) 
to under 140/90 mm Hg for uncomplicated hypertension, and 
less than 130/80 mmHg for those with diabetes mellitus or  
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renal disease [1]. Since monotherapy controls the BP of less 
than 50% of treated hypertensive patients [2, 3], combination 
therapy with two or more antihypertensive medications is 
often required to achieve BP control to recommended levels 
[1, 4]. At present, the most widely used antihypertensive 
combinations involve hydrochlorothiazide (HCTZ) and 
drugs that block the renin-angiotensin system (RAS), such as 
angiotensin-converting enzyme inhibitors (ACEIs) and an-
giotensin receptor blockers (ARBs). Recently a new blocker 
of the RAS, aliskiren, has been developed and approved by 
the US Food and Drug Administration (FDA, on 5
th March 
2007) and by the European Medicines Agency (EMEA, on 
22
nd August 2007) for the treatment of essential hyperten-
sion. Aliskiren is an oral direct renin inhibitor, the rate-
limiting enzyme in the production of the end product of the 
RAS cascade, angiotensin II, a potent vasoactive peptide. 
Aliskiren is a long-acting antihypertensive (half-life  40 
hours) and has been shown in several clinical trials to be 
effective in lowering BP, safe and well tolerated in daily 
doses of 150 and 300 mg (approved once-daily doses) [5]. In 
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blind randomized clinical trials to quantify the systolic and 
diastolic BP (SBP and DBP) lowering efficacy of aliskiren  
in the treatment of adults with essential hypertension,   
the obtained weighted mean differences with 95% CI were: 
aliskiren 150 mg, -5.5 (-6.5, -4.4)/-3.0 (-3.7, -2.3) mm Hg; 
aliskiren 300 mg, -8.7 (-9.7, -7.6)/-5.0 (-5.6, -4.3) mm Hg 
[5]. In double-blind randomized 8-week clinical trials,   
aliskiren/HCTZ combination therapy reduced SBP and   
DBP from baseline to a significantly greater extent than   
placebo, aliskiren monotherapy and HCTZ monotherapy   
[6, 7]. Aliskiren/HCTZ also produced significant additional 
SBP and DBP reductions in patients inadequately responsive 
to 4 weeks’ prior treatment with aliskiren or HCTZ   
alone [6]. 
  Single-pill combinations (SPCs) of aliskiren/HCTZ 
(150/12.5 mg, 150/25 mg, 300/12.5 mg, 300/25 mg) have 
recently been approved by the US FDA (18
th January 2008) 
and by EMEA (16
th January 2009) for the treatment of adults 
with essential hypertension whose BP is not adequately con-
trolled with aliskiren or HCTZ alone, and as a substitution 
treatment in patients with hypertension adequately treated by 
the two individual drugs concomitantly at the equivalent 
fixed dosage. There have been several reviews published 
with a general scope of pharmacology, pharmacodynamic 
and pharmacokinetic profile and clinical studies of   
aliskiren/HCTZ combination. In this paper, we performed a 
systematic analysis of the literature and a meta-analytical 
approach to the available clinical trial data for the various 
combinations of aliskiren/HCTZ to assess their antihyperten-
sive efficacy in the treatment of mild to moderate hyperten-
sion. 
  The aim of this review was to assess the antihypertensive 
efficacy and tolerability of the aliskiren/HCTZ combination 
therapy (as a combination of the individual components or as 
SPCs) in reducing SBP and DBP in patients with mild to 
moderate hypertension by using systematic analysis of the 
literature and meta-analytical approach to combine data from 
different randomized, double-blind, clinical trials. 
MATERIALS AND METHODOLY 
  A literature search to identify clinical trials using   
aliskiren in combination with HCTZ for the treatment of 
hypertension was conducted on December 2009 to obtain all 
published study reports that met our inclusion criteria. 
Inclusion and Exclusion Criteria 
  We included all articles in the literature written in any of 
the major languages. To be included in our review studies 
were required to be randomized, double-blind, clinical trials 
using aliskiren in combination with HCTZ (as a combination 
of the individual components or as SPCs) for the treatment 
of hypertension. Additionally, studies were included if   
they evaluated the antihypertensive efficacy (outcome   
measure) of aliskiren/HCTZ in patients with mild or moder-
ate essential hypertension (SBP 140-179 mm Hg and/or   
DBP 90-109 mm Hg, as defined in current international 
guidelines [4]) and patient age  18 years. Articles were 
automatically excluded if their results were not reported or 
had been presented in forms such as abstracts, letters, or 
commentaries. 
Literature Search Strategy 
  We searched the following electronic databases: Interna-
tional Pharmaceutical Abstracts, MEDLINE, The Cochrane 
Library and ISI Web of Knowledge. Each database was in-
dependently searched by 2 reviewers for articles published 
from 2000 to and including November 30, 2009, using   
the search terms aliskiren,  aliskiren/hydrochlorothiazide,  
aliskiren-hydrochlorothiazide, aliskiren in combination with 
hydrochlorothiazide, renin inhibitor. The reviewers selected 
articles based on the predefined inclusion/exclusion criteria 
and results were matched. A consensus method was applied 
to judge any article selection divergences. The rationale for 
decisions was discussed until reviewers agreed on the final 
decision. A third author was called to resolve any remaining 
discrepancies concerning article eligibility. 
  Selected articles’ references and reviews of the subject 
were hand searched for additional studies that were not   
obtained through our initial electronic search. 
Data Extraction 
  The following information was gathered for each clinical 
trial: author names, year of publication, study design and 
duration, setting, characteristics of the patients enrolled, 
sizes of the treatment groups, daily treatment regimens and 
primary endpoint. Outcomes extracted from articles included 
mean and variation of SBP and DBP at baseline and final 
assessments for each group, responder rate (DBP < 90 mm 
Hg or 10 mm Hg reduction from baseline) and BP control 
rate (SBP < 140 mm Hg and DBP < 90 mm Hg). Changes 
from baseline in plasma renin activity (PRA) and plasma 
renin concentration (PRC) with aliskiren/HCTZ and with 
either component alone were also extracted whenever re-
ported, as well as adverse events recorded during the trials. 
During the data extraction phase, we wrote to corresponding 
authors of studies to request missing data and clarify study 
details. 
Quality Assessment 
  The quality of selected articles was assessed by the same 
principles used in article selection and data extraction (i.e., 2 
independent reviewers), and was based on the Jadad et al. 
method to measure the risk of bias [8]. Their 3-item quality 
assessment checklist evaluates the following methodological 
parameters: controlled trial, random allocation of treatments, 
double-blind follow-up, dropout rate, intention-to-treat (ITT) 
analysis and absence of other biases. Quality scores were 
presented as proportions of the total possible score (i.e., 5) of 
the quality assessment scale (where 100% represents the 
maximum quality). The scores were categorized according to 
the following criteria: weak (<60%), fair (60%), good (80%), 
or very good (100%). 
Analysis Method 
  For trials meeting the criteria for inclusion in the analy-
sis, the efficacy of treatment was evaluated via measure-
ments of SBP and DBP at the start of the trial (baseline) and 
after 8 weeks of therapy. The meta-analytical approach 
therefore compared the efficacy of each aliskiren/HCTZ dose 
combination in reducing SBP and DBP over this period of 
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the mean BP reduction for a set of aliskiren/HCTZ dose 
combinations evaluated, by weighting the combined data for 
the trial size using the following formula: (BP reduction 
[trial 1] • number of patients [trial 1] +…+ BP reduction 
[trial n] • number of patients [trial n])/total number of   
patients (trial 1 +…+ trial n). 
RESULTS 
  A completed QUOROM flow chart [9] of the literature 
search strategy applied and results found is depicted in Fig. 
(1). Initially, 46 potentially relevant RCTs were identified 
that appeared to meet the inclusion criteria and were 
screened for retrieval based on their titles and abstracts. 
Thirty of those articles were excluded for not evaluating   
aliskiren in combination with hydrochlorothiazide. The   
remaining 16 articles were retrieved for full-text review. 
Eleven of those articles were excluded for the following   
reasons: two had data that were not extractable [10, 11], 
three presented excluded study designs [12-14], one enrolled 
patients with severe hypertension [15], four appeared only in 
the abstract form [16-19] and one was indexed in MEDLINE 
in duplicate [20]. Therefore, after exclusion criteria were 
applied, a total of 5 studies involving a total of 5508 patients 
were included in this analysis [20-24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Quorom flow chart of literature search strategy applied and 
results. Five double-blind randomized controlled trials met the in-
clusion criteria, using aliskiren in combination with HCTZ for the 
treatment of hypertension. 
 Table  1 presents the overall characteristics of the evalu-
ated studies. The average sample size was 1102 ± 947 (mean 
± SD), with a median of 722 and range from 489–2776 pa-
tients. All included studies were randomized, double-blind, 
multicenter clinical trials, proceeded by a single-blind, pla-
cebo [21] / active comparator [20, 22-24], run-in period of 2-
4 weeks. Moreover, all five studies specified the change 
from baseline (start of double-blind treatment) in mean sit-
ting DBP (msDBP) at 8 weeks as the primary endpoint. Sec-
ondary efficacy measures included the change in mean sit-
ting SBP (msSBP) [20-24], the proportion of patients with 
successful response to treatment (defined as msDBP < 90 
mmHg and/or a  10 mmHg reduction from baseline) [21, 
22] and the proportion of patients attaining BP control (de-
fined as msDBP < 90 mmHg and msSBP < 140 mm Hg) [20-
24]. Two trials used the SPC [21, 22], and three combined 
the individual components [20, 23, 24], with aliskiren   
and HCTZ administered orally as single daily doses in all 
studies. One trial enrolled obese hypertensive patients only 
(obesity defined as body mass index of  30 kg/m
2) [22],  
although in the remaining four trials subgroups of patients 
with obesity were also present. In the five included clinical 
trials patient demographics and baseline characteristics were 
similar across treatment groups. Brief details of the charac-
teristics of each individual trial and treatment group, includ-
ing mean patient ages, sex ratios, body mass index / obesity 
and baseline SBP and DBP are provided in Appendix. The 
average quality score of study reporting was 84% ± 22% 
(range 60–100%), which could be categorized as very good. 
One study failed to report all information on data variability 
[21], which prevented the use of an approximation for stan-
dard error of the mean (SEM) or confidence interval (CI) 
estimation, when calculating some weighted average reduc-
tions in SBP and DBP. We contacted the corresponding 
author of this study by email to request missing data on SEM 
as well as on BP control rate at endpoint for each   
aliskiren/HCTZ, aliskiren and HCTZ daily doses tested, but 
no response was provided. 
 Table  2 details results from clinical trials on the efficacy 
of aliskiren/HCTZ in reducing BP. In the only placebo-
controlled study (and also the largest of the RCTs),   
aliskiren/HCTZ combination reduced SBP and DBP from 
baseline to a significantly (p  0.0001) greater extent than 
placebo in patients with mild to moderate hypertension [21], 
furthermore, aliskiren/HCTZ combination (at all but the 
75/12.5 mg and 150/6.25 mg dosages, both of which are not 
commercially available) decreased SBP and DBP from base-
line to a significantly (p < 0.05) greater extent than the com-
ponent monotherapies [21]. In the other selected RCTs, all of 
which with an active comparator and a non-responder study 
design [20, 22-24], aliskiren/HCTZ combination was an ef-
fective treatment option, producing significantly additional 
reductions in SBP and DBP in patients with mild to moder-
ate hypertension inadequately responsive to 4 weeks’ prior 
treatment with aliskiren [20] or HCTZ [22-24] alone. In the 
five included RCTs, BP control rates were also significantly 
higher with all aliskiren/HCTZ combinations commercially 
available than with placebo, aliskiren alone and HCTZ alone. 
One of the included studies did not report the BP response 
rate [24], in the remaining four studies, BP response rates 
were also significantly higher with all aliskiren/HCTZ com-
binations commercially available than with placebo; how-
ever, only the three higher dosages of aliskiren/HCTZ com-
binations yielded significantly higher BP response rates than 
the component monotherapies [20-23]. Two studies also 
compared the efficacy of aliskiren/HCTZ 300/25 mg combi-
nation in reducing and controlling BP with other treatment Aliskiren/HCTZ Combination  The Open Cardiovascular Medicine Journal, 2011, Volume 5    9 
Table 1.  Published Clinical Trials of Aliskiren/HCTZ for Treatment of Mild to Moderate Hypertension 
Reference 
(Year) 
Study Design, 
Duration, Setting, 
BP measurement, 
No of patients 
Demographics and Baseline  
Characteristics
a 
Daily Treatment Regimens  Primary End Point  Quality 
Score
b 
Villamil 
(2007) [21] 
Randomized,  
double-blind,  
placebo-controlled, 
multicenter; 8 wks; 
clinic; trough BP; 
n=2776 
Age  18 yrs. Eligibility for single-blind 
phase: msDBP 95 and <110 mmHg  
(baseline). Eligibility for double-blind 
phase: msDBP 95 and <110 mmHg after 2 
or 4 wks on placebo. Mean age 55 yrs; 55% 
men; 86% Caucasian. 
Single-blind, placebo run-in period (2 wks or 4 
wks): Placebo. 
Double-blind treatment (8 wks): Placebo; 
Aliskiren 75, 150, 300mg; 
HCTZ 6.25, 12.5, 25mg; 
Aliskiren/HCTZ 75/6.25, 75/12.5, 75/25, 150/6.25, 
150/12.5, 150/25, 300/12.5, 300/25mg. 
Change in msDBP from 
baseline (start  
of double-blind  
treatment) to wk 8 
endpoint (aliskiren 
monotherapy vs  
placebo; combination 
therapy vs respective 
monotherapies) 
60%
c 
Jordan 
(2007) [22] 
Randomized,  
double-blind,  
multicenter; 12 
wks; clinic; trough 
BP; n=489 
Age  18 yrs. Eligibility for single-blind 
phase: msDBP 95 and <110 mmHg  
(baseline). Eligibility for double-blind 
phase: msDBP 90 and <110 mmHg. BMI 
 30 kg/m
2; Mean age 54 yrs; 44% men; 
99.6% Caucasian. 
Single-blind treatment (4 wks): HCTZ 25mg. 
Double-blind treatment (first 4 wks – next 8 wks): 
Placebo–HCTZ 25 – 25mg; 
Aliskiren/HCTZ 150/25 - 300/25mg; 
Irbesartan/HCTZ 150/25 – 300/25 mg; 
Amlodipine/HCTZ 5/25 – 10/25mg; 
Change in msDBP from 
baseline (start of  
double-blind treatment) 
to wk 8 endpoint  
(aliskiren/HCTZ 300/25 
mg vs placebo–HCTZ  
25 mg) 
100% 
Nickenig 
(2008) [20] 
Randomized,  
double-blind,  
multicenter; 8 wks; 
clinic; trough BP; 
n=880 
Age  18 yrs. Eligibility for single-blind 
phase: msDBP 95 and <110 mmHg or 
msDBP 85 and <110 mmHg if treated for 
HT within the 4 wks prior to screening 
(baseline). Eligibility for double-blind 
phase: msDBP 90 and <110 mmHg after 4 
wks of aliskiren 300 mg monotherapy. 
Mean age 55 yrs;55% men;83% Caucasian. 
Single-blind treatment (4 wks): Aliskiren 300mg. 
Double-blind treatment (8 wks): 
Aliskiren 300mg; 
Aliskiren/HCTZ 300/12.5, 300/25mg. 
Change in msDBP from 
baseline (start  
of double-blind  
treatment) to wk 8 
endpoint (aliskiren 
monotherapy vs  
combination therapy) 
100% 
Blumenstein 
(2009) [23] 
Randomized,  
double-blind,  
multicenter; 8 wks; 
clinic; trough BP; 
n=722 
Age  18 yrs. Eligibility for single- 
blind phase: patients with HT, who were 
newly diagnosed, untreated or treated at  
the time of screening. Newly diagnosed pts 
or pts who had not been treated for HT in 
the 4 wks prior to screening had to have 
msDBP 95 and <110 mmHg at the  
time of the screening. Eligibility for  
double-blind phase: msDBP 90 and  
<110 mmHg after 4 wks of HCTZ  
25 mg monotherapy. Mean age 54 yrs;  
59% men;91% Caucasian. 
Single-blind treatment (4 wks): HCTZ 25mg. 
Double-blind treatment (8 wks): 
HCTZ 25mg; 
Aliskiren/HCTZ 150/25, 300/25mg. 
Change in msDBP from 
baseline (start  
of double-blind  
treatment) to wk 8 
endpoint (HCTZ  
monotherapy vs  
combination therapy) 
100% 
Geiger 
(2009) [24] 
Randomized,  
double-blind,  
multicenter; 8 wks; 
clinic; trough BP; 
n=641 
Age  18 yrs. Eligibility for single-blind 
phase: pts with mild to moderate HT taking 
antihypertensive agents. 
Eligibility for double-blind phase: msDBP 
95 and <110 mmHg after 4 wks of HCTZ 
monotherapy. Mean age 53 yrs; 57% men; 
86% Caucasian. 
Single-blind treatment (4 wks): HCTZ 12.5mg for 
1 wk followed by HCTZ 25mg for 3 wks. 
Double-blind treatment (8 wks): HCTZ 25mg; 
Aliskiren/HCTZ 150/25mg for 4 wks followed by 
300/25mg for another 4 wks; 
Valsartan/HCTZ 160/25mg for 4 wks followed by 
320/25mg for another 4 wks; 
Aliskiren/Valsartan/HCTZ 150/160/25mg for 4 
wks followed by 300/320/25mg for another 4 wks. 
Change in msDBP from 
baseline (start  
of double-blind  
treatment) to wk 8 
endpoint  
(aliskiren/HCTZ  
and valsartan/HCTZ  
vs aliskiren/valsartan/ 
HCTZ) 
60%
d 
a In each published clinical trial, patient baseline and demographic characteristics were comparable for all treatment groups. 
bThe percentage of the total possible score (i.e., 5) of the quality assessment scale applied (100% represents the maximum quality). 
c Method to generate the sequence of randomization and method of double blind were not described; additionally, some information on outcome variability was not provided. 
d Method to generate the sequence of randomization and method of double blind were not described. 
BP; blood pressure; HCTZ – hydrochlorothiazide; HT – hypertension; msDBP – mean sitting diastolic blood pressure; pts – patients; wk – week. 10    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Morgado et al. 
Table 2. Clinical Trial Data on the Efficacy of Aliskiren/HCTZ in Reducing BP 
Reference  Patients, 
n (ITT) 
Treatment and Daily Dose (mg)  Change in SBP from 
Baseline at Endpoint 
(mm Hg) 
Change in DBP from 
Baseline at Endpoint 
(mm Hg) 
Responder 
Rate (%) 
BP Control Rate 
at Endpoint (%) 
Villamil 
(2007) [21] 
192 
183 
183 
180 
194 
188 
173 
187 
189 
186 
173 
184 
187 
180 
173 
Placebo 
Aliskiren 75 
Aliskiren 150 
Aliskiren 300 
HCTZ 6.25 
HCTZ 12.5 
HCTZ 25 
Aliskiren/HCTZ 75/6.25 
Aliskiren/HCTZ 75/12.5 
Aliskiren/HCTZ 75/25 
Aliskiren/HCTZ 150/6.25 
Aliskiren/HCTZ 150/12.5 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
-7.5 
-9.4 
-12.2
b 
-15.7
c 
-11.0
a 
-13.9
c 
-14.3
c 
-14.3 ±0.93
c,d 
-15.6
c 
-17.3
c,d 
-15.3
c 
-17.6
c,d 
-19.5
c,d 
-19.8
c,d 
-21.2±0.97
c,d 
-6.9 
-8.7±0.59
a 
-8.9±0.59
a 
-10.3±0.60
c 
-9.1±0.58
a 
-10.1±0.59
c 
-9.4±0.61
a 
-10.8
c,d 
-11.1
c 
-11.5
c,d 
-10.4±0.59
c 
-11.9
c,d 
-12.7
c,d 
-13.9
c,d 
-14.3±0.61
c,d 
45.8 
51.9 
51.9 
63.9
b 
53.6 
60.6
a 
59.0
a 
61.5
a 
63.5
b 
70.4
c,d 
58.4
a 
69.6
c 
71.1
c,d 
80.6
c,d 
76.9
c,d 
28.1 
(29.0 
to 
c 46.7) 
(32.5 
to 
37.8) 
a 
a 
a,d (37.4 
a to 
a,d 59.5) 
a,d 
a,d 
a,d 
Jordan 
(2007) [22] 
117 
113 
117 
122 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Irbesartan/HCTZ 300/25 
Amlodipine/HCTZ 10/25 
-8.6±1.00 
-15.8±1.01
e 
-15.4±1.00
h 
-13.6±0.98
h 
-7.9±0.73 
-11.9±0.74
e 
-11.3±0.72
h 
-10.3±0.71
h 
59.0 
73.5
f 
70.9
h 
68.0
h 
34.2 
56.6
g 
54.7
h 
45.1
i 
Nickenig 
(2008) [20] 
296 
292 
284 
Aliskiren 300 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
-8.0±0.9 
-13.5±0.9
j 
-15.9±0.9
j 
-7.4±0.5 
-10.5±0.5
j 
-11.0±0.6
j 
62.2 
73.3
k 
77.1
j 
40.9 
57.9
j 
60.2
j 
Blumenstein 
(2009) [23] 
244 
242 
232 
HCTZ 25 mg 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/25 
-7.1±0.7 
-12.9±0.7
l 
-16.7±0.7
l,m 
-4.8±0.4 
-8.5±0.4
l 
-10.7±0.4
l,n 
47.1 
67.4
l 
78.5
l 
25.8 
48.8
l 
58.2
l,o 
Geiger 
(2009) [24] 
151 
164 
154 
168 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Valsartan/HCTZ 320/25 
Aliskiren/Valsartan/HCTZ 300/320/25 
-6±1.12 
-15 ±1.08
l 
-18 ±1.12
l 
-22±1.07
l,p,q 
-6±0.70 
-11±0.67
l 
-14±0.70
l 
-16±0.67
l,p,q 
NR 
NR 
NR 
NR 
20.53 
40.85
l 
48.70
l 
66.67
l,p,r 
Changes in blood pressure are presented as the least-squares mean changes (with ± SEM, whenever provided by the authors). 
aP < 0.05, 
bP < 0.001, 
cP  0.0001 vs placebo; 
dP < 0.05 vs each component monotherapy; 
eP < 0.0001 vs HCTZ 25 mg; 
fP < 0.05 vs HCTZ 25 mg; 
gP = 0.0005 vs HCTZ 25 mg; 
hP > 
0.05 vs aliskiren/HCTZ 300/25 mg; 
iP = 0.052 vs aliskiren/HCTZ 300/25 mg; 
jP < 0.001 vs aliskiren 300 mg; 
kP = 0.002 vs aliskiren 300 mg; 
lP < 0.001 vs HCTZ 25 mg; 
mP = 0.009 
vs aliskiren/HCTZ 150/25 mg; 
nP < 0.001 vs aliskiren/HCTZ 150/25 mg; 
oP = 0.033 vs aliskiren/HCTZ 150/25 mg; 
pP < 0.001 vs aliskiren/HCTZ 300/25 mg; 
qP < 0.01 vs valsar-
tan/HCTZ 320/25 mg; 
rP < 0.001 vs valsartan/HCTZ 320/25 mg. 
BP – Blood pressure; DBP – Diastolic blood pressure; HCTZ – Hydrochlorothiazide; ITT – Intention-to-treat analysis; NR – Not reported; SBP – Systolic blood pressure. 
 
combinations (amlodipine/HCTZ 10/25 mg, irbesartan/   
HCTZ 300/25 mg, valsartan/HCTZ 320/25 mg and aliskiren/ 
valsartan/HCTZ 300/320/25 mg) [22, 24]. Only the last 
combination yielded significantly greater decreases in SBP 
and DBP and higher BP control rates than the aliskiren/ 
HCTZ 300/25 mg combination [24]. 
 Table  3 presents the weighted mean reductions from 
baseline of SBP and DBP and BP control rate for each al-
iskiren/HCTZ combination commercially available. It should 
be noted that four RCTs were not placebo-controlled and, 
furthermore, the active comparator (aliskiren or HCTZ) dif-
fered in these studies [20, 22-24]. In these circumstances, 
appraisal of the change from baseline in SBP and DBP 
achieved by each aliskiren/HCTZ combination allows some 
appreciation of their antihypertensive efficacy since all data 
are derived from studies of similar design. Nevertheless, the 
higher BP reductions reported in the Villamil (2007) trial 
[21] with aliskiren/HCTZ (a fact also observed with aliskiren 
and HCTZ monotherapies) must be observed with some   
caution, as they clearly diverged upward from the results Aliskiren/HCTZ Combination  The Open Cardiovascular Medicine Journal, 2011, Volume 5    11 
obtained by other authors and yielded an unexpected higher 
effect of the lowest dose of aliskiren/HCTZ commercially 
available (150/12.5 mg). 
  Some authors also studied changes from pre-treatment 
[22] (start of single-blind treatment) or baseline [21, 24] 
(start of double-blind treatment) in PRA and PRC with al-
iskiren and HCTZ monotherapy and combination therapy. 
Aliskiren 75, 150 and 300 mg/day decreased (the geometric) 
PRA from baseline by 54.2%, 65.1% and 57.6%, respec-
tively [21]. Conversely, HCTZ monotherapy significantly 
increased PRA at 12.5 and 25 mg/day dosages [21, 22]. 
When combined, aliskiren/HCTZ significantly reduced PRA 
from pretreatment (by 45%) [22] and baseline (by 40.5-
62.3%) [21, 24], whereas combined treatment with amlodip-
ine/HCTZ, irbesartan/HCTZ and valsartan/HCTZ signifi-
cantly increased PRA [22, 24]. Aliskiren elevated PRC from 
baseline in a dose-dependent manner, with increases of 
164%, 192% and 348% at dosages of 75, 150 and 300 
mg/day, respectively [21]. HCTZ 25 mg/day increased PRC 
by 108%, whereas lower dosages did not cause alterations in 
PRC that significantly differed from placebo. All aliskiren/ 
HCTZ combinations significantly increased PRC [21, 24], 
the magnitude of increases was related to the dosages of both 
components, with the most marked increase (1211% from 
baseline) occurring in the aliskiren/HCTZ 300/25 mg group 
[21]. Furthermore, increases in PRC in several combination 
groups were considerably greater than the sum of the in-
creases seen with each component [21]. It should be noted 
that Geiger et al. measured the baseline PRA and PRC at the 
end of the 4-week single-blind HCTZ period [24]. Therefore, 
the effect of HCTZ on PRA and PRC might have been stabi-
lized with this initial therapy and no further changes after the 
8-week additional HCTZ treatment was observed [24]. 
  Each published study also describes the most common 
adverse events reported in the clinical trials. Aliskiren/ 
HCTZ, as a SPC or as a combination of the individual   
components concurrently administered, was generally well 
tolerated in the five clinical trials reviewed. The majority of 
adverse events were mild and transient in nature, with the 
most commonly reported events including nasopharyngitis 
[20-24], headache [20-24], dizziness [22, 23], back pain [23], 
vertigo [23] and hypercholesterolemia [20]. The proportion 
of patients experiencing hypokalaemia (defined as serum 
potassium levels <3.5 mmol/L) were numerically lower with 
aliskiren/HCTZ than with HCTZ alone [21, 23, 24]. The 
proportion of patients with hypokalemia was also lower in 
the aliskiren/HCTZ 300/12.5 mg group (0.4%) and aliskiren 
300 mg monotherapy group (0.4%) than in the aliskiren/ 
HCTZ 300/25 mg group (2.5%) [20]. In obese hypertensive 
patients, hypokalemia occurred in 4.9% patients of the   
aliskiren/HCTZ group versus 2.5%, 10.3% and 4.1% of   
patients treated with irbesartan/HCTZ, amlodipine/HCTZ or 
HCTZ alone, respectively [22]. 
DISCUSSION 
  SPCs of aliskiren/HCTZ has recently been introduced in 
European Union for the second-line treatment of adults with 
essential hypertension whose BP is not adequately controlled 
with either drug alone, or as a substitution treatment in pa-
tients with hypertension adequately treated by the two indi-
vidual drugs concomitantly at the equivalent fixed dosage. 
To our knowledge, this study represents the first published 
meta-analytical approach to the efficacy of aliskiren/HCTZ 
in reducing BP in patients with mild to moderate hyperten-
sion. Although other reviews dealing with the same topic are 
available in the literature, no study has provided a synthesis 
of data from clinical trials. 
  The five studies included in this systematic review are 
short-term (8-12 weeks) randomized, double-blind, clinical 
trials with a similar design and comparable primary end-
points and secondary efficacy measures. All studies com-
pared the  change in SBP and DBP from baseline (start of 
double-blind treatment) to week 8 endpoint in each al-
iskiren/HCTZ combination group with that in placebo and/or 
aliskiren monotherapy and/or HCTZ monotherapy group. 
Patient demographics and baseline characteristics were also 
similar across treatment groups in all included studies, except 
that one study included obese patients only [22]. The average 
quality of the articles was considered to be very good. 
  In this study we chose to present the results by way of 
weighted average sums of BP reductions over 8 weeks, a 
period consistent with current clinical recommendations for 
Table 3. Weighted Average Reductions From Baseline of SBP and DBP and BP Control Rate for Each Aliskiren/HCTZ Combination 
Commercially Available 
Aliskiren/HCTZ  
Combination Evaluated 
Number of 
Clinical Trials 
Total number 
of Patients 
Change in SBP from Baseline 
at Endpoint (mm Hg) 
Change in DBP from Baseline 
at Endpoint (mm Hg) 
BP Control 
Rate (%)
a 
Aliskiren/HCTZ 150/12.5 mg  1  184  -17.6  -11.9  [37.4, 59. 5]
a 
Aliskiren/HCTZ 150/25 mg  2  429  -15.8  -10.3  [43.8, 53. 5]
a 
Aliskiren/HCTZ 300/12.5 mg  2  472  -15.9  -11.8  [50.1, 58. 5]
a 
Aliskiren/HCTZ 300/25 mg  5  966  -16.9±0.4  -11.6±0.3  [51.9, 55. 9]
a 
Changes in blood pressure are presented as the weighted least-squares mean changes ± SEM (not all variability information was provided in the trial of Villamil (2007) [21], prevent-
ing the use of an approximation for SEM or confidence intervals estimation for the first three aliskiren/HCTZ dose combinations). 
aThe range presented is due to the trial of Villamil (2007) [21], which presented the range of BP control rate for aliskiren/HCTZ combination, without specify the values for each 
dose combination. 
BP – Blood pressure; DBP – Diastolic blood pressure; HCTZ – Hydrochlorothiazide; SBP – Systolic blood pressure. 12    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Morgado et al. 
assessing the clinical efficacy and tolerability of antihyper-
tensive drugs following their initiation [1, 4]. The weighted 
means method, which has been used in other meta-analyses 
[25-27], takes into account the different sizes of trials and 
provides results that are easy to interpret clinically. 
  In all clinical trials selected for analysis, commercially 
available aliskiren/HCTZ combinations (150/12.5 mg, 
150/25 mg, 300/12.5 mg and 300/25 mg) provided clinically 
significant additional SBP and DBP reductions and im-
proved BP control rates over aliskiren or HCTZ monother-
apy, which demonstrates that aliskiren/HCTZ SPCs are a 
effective treatment option for patients with mild to moderate 
hypertension who do not achieve BP control with aliskiren 
300 mg or HCTZ 25 mg alone. A meta-analysis of 354 ran-
domized clinical trials involving more than 40,000 treated 
patients with hypertension revealed that the additional reduc-
tion in BP achieved with antihypertensive combination ther-
apy versus monotherapy provide a reduced risk of stroke and 
ischemic heart events [28]. In another meta-analysis, exam-
ining individual data from one million adults in 61 prospec-
tive studies, it was found that, at ages 40-69 years, each in-
crease of 20 mm Hg usual SBP (or, approximately equiva-
lently, 10 mm Hg usual DBP) is associated with more than a 
twofold difference in the stroke death rate, and with twofold 
differences in the death rates from ischaemic heart disease 
and from other vascular causes [29]. Thus, the additional 
mean BP reductions of up to 8.0/4.8 mmHg (versus HCTZ 
25 mg) or 6.0/3.1 mmHg (versus aliskiren 300 mg) provided 
by aliskiren/HCTZ 300/25 mg in the present analysis might 
be expected to reduce the risk of cardiovascular mortality. 
However, long-term and large-scale studies analysing the 
effects of aliskiren/HCTZ combination therapy on clinical 
outcomes are required to confirm this hypothesis. 
  The capacity of aliskiren to enhance the antihypertensive 
efficacy of HCTZ reflects its complementary mode of action, 
targeting the RAS at its point of activation and thus sup-
pressing PRA. HCTZ monotherapy increased PRA, as a re-
sult of stimulated renin release in response to reduced in-
travascular volume. The addition of aliskiren counteracted 
this effect, resulting in a significant (p < 0.05) overall de-
crease in PRA compared with HCTZ monotherapy [21, 22, 
24]. Furthermore, aliskiren effectively inhibited the renin 
enzyme, despite marked elevation in PRC, to produce an 
overall reduction in PRA from baseline. This contrasts to 
agents that block the RAS at other points, such as ACEIs and 
ARBs, which induce increases in PRA in parallel with PRC 
[22, 24, 30]. 
  Aliskiren/HCTZ was generally well tolerated in the clini-
cal trials reviewed and not associated with a notably higher 
incidence of adverse events than treatment with either com-
ponent alone. These results are consistent with a long-term 
open-label study in 1955 hypertensive patients showing that 
aliskiren/HCTZ free combinations were well tolerated over 
up to 12 months of treatment [16, 19]. In three included trials, 
when aliskiren and HCTZ were administered in combination, 
aliskiren opposed the adverse hypokalaemic effects of HCTZ 
[21, 23, 24]. The safety profile of an aliskiren/valsartan/ 
HCTZ combination was also investigated in one clinical trial 
and was similar to the 2-drug combinations (aliskiren/HCTZ 
or valsartan/HCTZ), with a greater BP-lowering effect in 
patients not adequately responding to HCTZ monotherapy 
[24]. 
  Most patients with hypertension will require combination 
treatment with two or more antihypertensive medications in 
order to achieve BP control to recommended levels [1, 4]. A 
meta-analysis of adherence studies showed that the use of 
SPC regimens reduced the rate of non-compliance by 24–
26% compared with respective free combinations [31].   
Aliskiren/HCTZ SPCs therefore offers the convenience of   
a single-tablet once daily treatment regimen, which may   
improve treatment compliance and subsequent BP control. 
  The limitations of this study should be noted. The inter-
vention effect size as reported above (Tables 2 and 3) could 
be an overestimate due to publication bias since the manu-
facturer (Novartis Pharmaceuticals Corporation) sponsored 
four [20, 22-24] of the included published studies and one 
author of the remaining study [21] is employee of Novartis 
Pharmaceuticals Corporation. It is possible that less optimis-
tic studies have not been published and therefore not in-
cluded in our analysis. In addition, because the BP lowering 
efficacy estimate is limited to 8 weeks, we cannot extrapo-
late our results to the longer term benefits of the treatments 
on cardiovascular morbidity and mortality. However, in this 
regard, the 2007 European Society of Hypertension (ESH)/ 
European Society of Cardiology (ESC) guidelines are perti-
nent, which state that the size of BP reduction is more impor-
tant than the class used for cardiovascular event reduction 
[4]. One other limitation is based on the fact that there is 
only one clinical trial investigating the antihypertensive effi-
cacy of the lowest dose of aliskiren/HCTZ commercially 
available (150/12.5 mg), which, additionally, lacks informa-
tion on outcome variability (SEM or CI) [21]. This fact was 
responsible for an unexpected higher efficacy of al-
iskiren/HCTZ 150/12.5 mg in reducing SBP and DBP, when 
compared with higher combination dosages (Table 3). Fur-
ther studies are required to accurately evaluate the dose-
related antihypertensive efficacy of the commercially avail-
able aliskiren/HCTZ combinations. 
  In conclusion, aliskiren/HCTZ combinations commer-
cially available were effective and generally well tolerated in 
clinical trials evaluating its antihypertensive effects in adults 
with mild to moderate hypertension and in hypertensive pa-
tients with obesity, providing clinically significant additional 
BP reductions and improved BP control rates in patients who 
are inadequately controlled with aliskiren or HCTZ mono-
therapy. The aliskiren/HCTZ SPCs present the convenience 
of a once-daily single-tablet treatment regimen, which may 
improve treatment adherence and subsequent BP control. 
Further studies are required to evaluate the relative benefits 
of the aliskiren/HCTZ SPCs with generically available alter-
natives. Also, long-term trials evaluating the efficacy and 
tolerability of this combination therapy would be of interest 
to establish the ultimate effects of treatment on the cardio-
vascular morbidity and mortality of hypertension. 
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